Viking Almost Triples After Fatty Liver Drug Meets Study Goals

(Bloomberg) -- Shares of Viking Therapeutics Inc. soared as much as 122 percent intraday hitting a record after the company said initial results for an experimental therapy for fatty liver disease ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.